Wedbush Assumes Texas Capital Bancshares at Neutral, Announces Price Target of $60
Wedbush analyst David Chiaverini assumes Texas Capital Bancshares (NASDAQ:TCBI) with a Neutral rating and announces Price Target of $60.
Wedbush Assumes Citizens Financial Group at Outperform, Announces Price Target of $44
Wedbush analyst David Chiaverini assumes Citizens Financial Group (NYSE:CFG) with a Outperform rating and announces Price Target of $44.
Wedbush Assumes BOK Financial at Neutral, Announces Price Target of $90
Wedbush analyst David Chiaverini assumes BOK Financial (NASDAQ:BOKF) with a Neutral rating and announces Price Target of $90.
Wedbush Assumes U.S. Bancorp at Neutral, Announces Price Target of $47
Wedbush analyst David Chiaverini assumes U.S. Bancorp (NYSE:USB) with a Neutral rating and announces Price Target of $47.
Wedbush Assumes Comerica at Outperform, Announces Price Target of $95
Wedbush analyst David Chiaverini assumes Comerica (NYSE:CMA) with a Outperform rating and announces Price Target of $95.
Wedbush Assumes Huntington Bancshares at Neutral, Announces Price Target of $14
Wedbush analyst David Chiaverini assumes Huntington Bancshares (NASDAQ:HBAN) with a Neutral rating and announces Price Target of $14.
Wedbush Assumes Fifth Third Bancorp at Outperform, Announces Price Target of $39
Wedbush analyst David Chiaverini assumes Fifth Third Bancorp (NASDAQ:FITB) with a Outperform rating and announces Price Target of $39.
Wedbush Assumes New York Community at Neutral, Announces Price Target of $10
Wedbush analyst David Chiaverini assumes New York Community (NYSE:NYCB) with a Neutral rating and announces Price Target of $10.
Maxim Group Initiates Coverage On BioRestorative Therapies with Buy Rating, Announces Price Target of $6
Maxim Group analyst Michael Okunewitch initiates coverage on BioRestorative Therapies (NASDAQ:BRTX) with a Buy rating and announces Price Target of $6.
Redburn Partners Initiates Coverage On Sabre with Buy Rating
Redburn Partners analyst James Goodall initiates coverage on Sabre (NASDAQ:SABR) with a Buy rating.